Phathom Pharmaceuticals (PHAT) Current Deferred Revenue (2023 - 2025)
Historic Current Deferred Revenue for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to $24.3 million.
- Phathom Pharmaceuticals' Current Deferred Revenue rose 2055.07% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 2055.07%. This contributed to the annual value of $19.8 million for FY2024, which is 17811.84% up from last year.
- As of Q3 2025, Phathom Pharmaceuticals' Current Deferred Revenue stood at $24.3 million, which was up 2055.07% from $21.5 million recorded in Q2 2025.
- Phathom Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $24.3 million during Q3 2025, with a 5-year trough of $276000.0 in Q2 2023.
- In the last 3 years, Phathom Pharmaceuticals' Current Deferred Revenue had a median value of $16.9 million in 2024 and averaged $13.9 million.
- Per our database at Business Quant, Phathom Pharmaceuticals' Current Deferred Revenue soared by 349057.97% in 2024 and then surged by 479.43% in 2025.
- Quarter analysis of 3 years shows Phathom Pharmaceuticals' Current Deferred Revenue stood at $7.1 million in 2023, then surged by 178.12% to $19.8 million in 2024, then rose by 23.09% to $24.3 million in 2025.
- Its Current Deferred Revenue stands at $24.3 million for Q3 2025, versus $21.5 million for Q2 2025 and $17.3 million for Q1 2025.